苏州博奥明赛

BioMinds is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative antibody-based therapeutics. The company utilizes its proprietary Omni-Minds fully human antibody platform and M-VHH nanobody platform to create a diverse pipeline of monoclonal, bispecific, and multi-specific antibodies. BioMinds focuses on high-impact therapeutic areas, particularly oncology and autoimmune diseases, by targeting validated and novel immune pathways. Their lead candidate, BM001, is a bispecific antibody targeting PD-L1 and 4-1BB currently in clinical development. Through strategic collaborations and internal R&D, BioMinds aims to deliver next-generation biologics that overcome the limitations of current standard-of-care treatments. The leadership team brings extensive experience from global pharmaceutical companies, positioning BioMinds as a rising player in the Chinese biopharma ecosystem.